Q/C TECHNOLOGIES, INC.
QCLS evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Market Cap:
- $6.3M
- Lead Asset:
- isomyosamine (Phase 2)
What it means
What to watch
Prepared research question
What matters most for QCLS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · QCLS
Q/C TECHNOLOGIES, INC. (QCLS) is a biotech company developing isomyosamine (Phase 2) for inflammatory and autoimmune conditions and supera-cbd (preclinical) for CNS disorders, with very limited cash and ongoing net losses.
Key risk: Low cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$6.3M
Cash Runway
—
Lead Asset
isomyosamine (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Q/C TECHNOLOGIES, INC..
Q/C TECHNOLOGIES, INC. (QCLS) is a biotech company developing isomyosamine (Phase 2) for inflammatory and autoimmune conditions and supera-cbd (preclinical) for CNS disorders, with very limited cash and ongoing net losses.
- Lead candidate isomyosamine is in Phase 2 for sarcopenia, frailty, autoimmune disease, rheumatoid arthritis, inflammatory bowel disease, and Hashimoto thyroiditis [pipeline].
- Second candidate supera-cbd is in preclinical development for epilepsy, pain, anxiety/depression, and addiction [pipeline].
- Cash & equivalents were $0.3M as of 2026-06-30 [sec].
- Net income was -$6.6M for the period ended 2026-06-30 [sec].
- Shareholders' equity was $16.1M as of 2026-06-30 [sec].
What works
- Isomyosamine targets a broad range of inflammatory and autoimmune indications, potentially addressing large markets [pipeline].
- The company has two active Phase 3 trials (NCT05438407 and NCT05693129) for isomyosamine, indicating progression toward later-stage development [catalyst].
What to weigh
- Cash & equivalents are very low at $0.3M as of 2026-06-30, which may limit operational runway [sec].
- The company reported a net loss of -$6.6M for the period ended 2026-06-30, indicating ongoing negative cash flow [sec].
- Supera-cbd is only at preclinical stage and faces competition from multiple Phase 3 epilepsy trials by companies such as Rapport Therapeutics, Stoke Therapeutics, and Longboard Pharmaceuticals [competitor_trial].
From the filings
Quoted directly from source documents.
Lead candidate isomyosamine is in Phase 2 for multiple indications.
“Pipeline Candidate: isomyosamine Indication: sarcopenia, frailty, autoimmune disease, rheumatoid arthritis, inflammatory bowel disease, Hashimoto thyroiditis Phase: Phase 2”
Two Phase 3 trials for isomyosamine are active and not recruiting.
“Phase 3 Topline: An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of L - NCT: NCT05438407. Status: Active, not recruiting.”
Catalysts
Catalyst timeline
- 2026-12-30 · Phase3_Topline: Phase 3 Topline: An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of L - NCT: NCT05438407 — Topline results from this active, not-recruiting Phase 3 trial will provide safety and efficacy data for isomyosamine.
- 2028-10-28 · Phase3_Topline: Phase 3 Topline: An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of L - NCT: NCT05693129 — Topline results from this active, not-recruiting Phase 3 trial will provide additional safety and efficacy data for isomyosamine.
Risks & what to watch (3)›
Key risks
- Low cash runway — Cash & equivalents of $0.3M as of 2026-06-30 may be insufficient to sustain operations without additional funding [sec].
- Ongoing net losses — Net loss of -$6.6M for the period ended 2026-06-30 indicates negative cash flow [sec].
- Preclinical stage for supera-cbd — Supera-cbd is preclinical and faces multiple Phase 3 competitors in epilepsy [pipeline][competitor_trial].
What to watch
- Phase 3 topline results for isomyosamine from trial NCT05438407, expected around 2026-12-30 [catalyst].
- Phase 3 topline results for isomyosamine from trial NCT05693129, expected around 2028-10-28 [catalyst].
- Any financing or partnership announcements given the low cash position [sec].
Sources: Catalysts · Competitor trials · Pipeline · Generated October 3, 2026 · How we verify sources →
Run Q/C TECHNOLOGIES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Q/C TECHNOLOGIES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.24 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 13, 2026- % of float
- 91.5%
- Days to cover
- 3.7
- Shares short
- 1,331,165
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
QCLS short interestFrequently asked questions
What is the AI investment thesis for Q/C TECHNOLOGIES, INC.?
Q/C TECHNOLOGIES, INC. (QCLS) is a biotech company developing isomyosamine (Phase 2) for inflammatory and autoimmune conditions and supera-cbd (preclinical) for CNS disorders, with very limited cash and ongoing net losses.
What is Q/C TECHNOLOGIES, INC.'s lead drug candidate?
Q/C TECHNOLOGIES, INC.'s most advanced tracked candidate is isomyosamine (Phase 2) for sarcopenia, frailty, autoimmune disease, rheumatoid arthritis, inflammatory bowel disease, Hashimoto thyroiditis.
Where is Q/C TECHNOLOGIES, INC. headquartered?
Q/C TECHNOLOGIES, INC. (QCLS) is headquartered in New York, NY, United States.
What therapeutic areas does Q/C TECHNOLOGIES, INC. focus on?
Q/C TECHNOLOGIES, INC. develops therapies across Neurology, Immunology, Pain, Musculoskeletal, Endocrinology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.